Price T Rowe Associates Inc. MD increased its holdings in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 3.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 245,885,918 shares of the company's stock after buying an additional 8,211,748 shares during the period. Kenvue comprises approximately 0.6% of Price T Rowe Associates Inc. MD's investment portfolio, making the stock its 23rd largest holding. Price T Rowe Associates Inc. MD owned approximately 12.82% of Kenvue worth $5,249,665,000 as of its most recent SEC filing.
A number of other large investors also recently added to or reduced their stakes in KVUE. Norges Bank acquired a new position in shares of Kenvue during the 4th quarter valued at about $521,348,000. Franklin Resources Inc. increased its holdings in shares of Kenvue by 61.5% during the 4th quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company's stock worth $912,059,000 after buying an additional 16,269,721 shares during the last quarter. Massachusetts Financial Services Co. MA raised its position in shares of Kenvue by 12.3% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company's stock valued at $2,085,070,000 after buying an additional 10,682,003 shares during the period. Boston Partners lifted its holdings in Kenvue by 36.9% in the fourth quarter. Boston Partners now owns 23,595,963 shares of the company's stock valued at $503,145,000 after acquiring an additional 6,366,097 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Kenvue during the fourth quarter worth $98,926,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
KVUE has been the topic of several research reports. Redburn Atlantic initiated coverage on Kenvue in a research note on Thursday, April 10th. They set a "neutral" rating and a $23.50 target price on the stock. Piper Sandler boosted their price objective on Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a research report on Monday, February 24th. UBS Group lowered their price target on shares of Kenvue from $23.00 to $21.00 and set a "neutral" rating for the company in a report on Friday, February 7th. Barclays dropped their target price on Kenvue from $23.00 to $22.00 and set an "equal weight" rating on the stock in a report on Monday, April 14th. Finally, Royal Bank of Canada reaffirmed a "sector perform" rating and set a $24.00 price objective on shares of Kenvue in a research report on Monday, February 3rd. Eight investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $24.42.
Check Out Our Latest Stock Analysis on Kenvue
Kenvue Price Performance
NYSE KVUE traded down $0.04 during mid-day trading on Monday, hitting $22.98. The stock had a trading volume of 2,393,922 shares, compared to its average volume of 15,755,179. The company has a 50 day simple moving average of $23.03 and a 200 day simple moving average of $22.45. The company has a market cap of $44.08 billion, a price-to-earnings ratio of 43.35, a P/E/G ratio of 2.62 and a beta of 1.02. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.46. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66.
Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Equities analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.
Kenvue Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th will be paid a dividend of $0.205 per share. The ex-dividend date of this dividend is Wednesday, May 14th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.57%. Kenvue's dividend payout ratio (DPR) is 154.72%.
About Kenvue
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Recommended Stories
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
